Intec Pharma Advances Medical Cannabinoid Development Program With Dosing of First Patient in a Phase 1 Pharmacokinetic Study of Accordion Pill-THC

Pursuing medical cannabinoids for a variety of pain indications

JERUSALEM, Jan. 2, 2019 /PRNewswire/ — Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces the dosing of the first patient in a Phase 1 pharmacokinetic (PK) study of AP-THC, its proprietary Accordion Pill™ platform containing synthetic tetrahydrocannabinol (THC), one of the primary cannabinoids contained in cannabis.

The Phase 1 PK study is a single-center, single-dose, randomized, open-label three-way crossover study to investigate the PK, safety and tolerability of AP-THC in up to 18 normal healthy volunteers.

“We are very pleased to be advancing our medical cannabinoid development program as we believe the Accordion Pill’s gastric retentive technology is ideally suited to extend the absorption phase of THC, with the goal of a slower rate of rise and more consistent drug plasma levels after oral delivery.  The combination of the slower rate of rise with sustained and consistent plasma levels is

... read more at: https://www.biospace.com/article/releases/intec-pharma-advances-medical-cannabinoid-development-program-with-dosing-of-first-patient-in-a-phase-1-pharmacokinetic-study-of-accordion-pill-thc/

by